The effect of different parenteral administration routes (i.d., s.c., i.v.), infusion rates, and albumin contents of the drug vehicle on the cumulative recovery of recombinant human interferon alpha-2a (rIFN alpha-2a) in lymph and on its concentration in blood and lymph was determined in sheep. Blood samples were withdrawn from a jugular vein catheter and lymph was collected from a cannulated efferent popliteal lymphatic duct. The concentration of rIFN alpha-2a in lymph and blood plasma samples was measured by an enzyme immunoassay. Following i.v. infusion of 2 x 10(7) U of rIFN alpha-2a, the peak concentrations measured in blood plasma and lymph, respectively, were 8250 and 14 U/ml. The concentration measured in lymph after i.d. or s.c. administration of the same dose was about 10(5) times higher (peak concentration, 3.1 x 10(6) U/ml), while blood plasma levels remained low (peak concentration, 315 U/ml). The cumulative recovery of rIFN alpha-2a in lymph following i.d. or s.c. administration was 59.2 +/- 7% (mean +/- SD; N = 8) and was affected neither by the infusion rate nor by the coadministration of albumin. Our data indicate that following i.d. or s.c. administration, rIFN alpha-2a (MW 19,000) is absorbed mainly by the lymphatics. This results in high levels of rIFN alpha-2a in the lymph which drains from the application site to the regional lymph nodes. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of protein drugs whose targets are lymphoid cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1015957022073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pegylated interferon: the who, why, and how.
Hematology Am Soc Hematol Educ Program
December 2024
Hopital Saint-Louis, Paris Cité University, Inserm CIC 1427, Paris, France.
Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms. Indeed, IFN-α has been used for decades across all myeloproliferative neoplasms, but only recently a new form, ropegIFN-α2b, was approved to treat patients with polycythemia vera.
View Article and Find Full Text PDFEvaluation of efficacy, safety and underlying mechanism on Traditional Chinese medicine as synergistic agents for cancer immunotherapy: A preclinical systematic review and meta-analysis.
J Ethnopharmacol
February 2025
Department of Integrated Traditional Chinese and Western Medicine, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ethnopharmacological Relevance: Based on the documentation in Shennong's Herbal Classics, numerous Traditional Chinese medicine (TCM) are noted to possess anti-tumor properties, and TCM has been used in China for thousands of years. Particularly, current research have demonstrated that TCM combined with immunotherapy exhibited enhanced anti-tumor effects.
Aim Of The Study: This meta-analysis aimed to evaluate the effectiveness, security, and potential mechanisms of TCM coupled with programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors in cancer animal models.
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates.
Pathol Res Pract
November 2024
Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy. Electronic address:
Article Synopsis
- Hepatoid thymic carcinoma (HTC) is a rare tumor that looks similar to liver cancer, specifically found in the thymus gland, and a new case has been identified in a 40-year-old man with polycythemia vera.
- This case involved advanced analysis of the tumor's molecular profile, noting the presence of various proteins through immunohistochemistry and significant mutations identified via whole exome sequencing.
- The study suggests that HTC may represent an evolutionary shift in tumor characteristics, combining features of both thymic carcinoma and hepatoid tumors, indicated by the unique mutation patterns found in the cells.
Highly selective split intein method for efficient separation and purification of recombinant therapeutic proteins from mammalian cell culture fluid.
J Chromatogr A
November 2024
William G. Lowrie Department of Chemical and Biomolecular Engineering, Ohio State University, Columbus, OH 43210, United States; Protein Capture Science LLC, Columbus, OH 43212, United States. Electronic address:
Biologics and vaccines have been successfully developed over the last few decades to treat many diseases. Each of these drugs must be highly purified for clinical use. Monoclonal antibodies (mAbs), the dominant therapeutic modality on the market, can be easily purified using the standard Protein A affinity platform.
View Article and Find Full Text PDFPredicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis.
BMC Infect Dis
October 2024
Department of infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital, of Wenzhou Medical University, Wenzhou, China.
Background: The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.
Methods: We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!